Literature DB >> 3048471

Veno-occlusive disease of the liver following high-dose chemotherapy and autologous bone marrow transplantation in children with solid tumors: incidence, clinical course and outcome.

L Brugieres1, O Hartmann, E Benhamou, E S Zafrani, J M Caillaud, C Patte, C Kalifa, F Flamant, J Lemerle.   

Abstract

Two hundred and thirty-six consecutive courses of high-dose chemotherapy with autologous bone marrow transplantation in children with solid tumors were reviewed in order to assess the incidence, clinical presentation and outcome of veno-occlusive disease (VOD) of the liver. Patients conditioned with total body irradiation were excluded from this study. Eleven patients (4.6%) met the diagnostic criteria for VOD. The clinical course included sudden weight gain, jaundice, hepatomegaly and ascites. Renal dysfunction and refractoriness to platelet transfusions occurred in the most severe forms. Seven patients recovered within 7-29 days of onset and four patients died, all with renal failure and fluid overload. The time of onset appeared to determine two patterns of outcome: mild forms with early onset (before day 11) and more severe forms with onset after day 17. Analysis of pretransplant factors revealed no significant association with an increased risk of VOD. However, all the patients with severe VOD had received a conditioning regimen containing cyclophosphamide which might be involved in the pathogenesis of VOD.

Entities:  

Mesh:

Year:  1988        PMID: 3048471

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  6 in total

Review 1.  Sinusoidal obstruction syndrome (hepatic veno-occlusive disease).

Authors:  Cathy Q Fan; James M Crawford
Journal:  J Clin Exp Hepatol       Date:  2014-10-30

2.  Phase I trial of indicine-N-oxide in children with leukemia and solid tumors: a Pediatric Oncology Group study.

Authors:  V M Whitehead; M L Bernstein; R Vega; T Vats; P Dyment; T J Vietti; J Krischer
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

Review 3.  Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome.

Authors:  Jason A Coppell; Paul G Richardson; Robert Soiffer; Paul L Martin; Nancy A Kernan; Allen Chen; Eva Guinan; Georgia Vogelsang; Amrita Krishnan; Sergio Giralt; Carolyn Revta; Nicole A Carreau; Massimo Iacobelli; Enric Carreras; Tapani Ruutu; Tiziano Barbui; Joseph H Antin; Dietger Niederwieser
Journal:  Biol Blood Marrow Transplant       Date:  2009-09-18       Impact factor: 5.742

4.  Busulfan disposition and hepatic veno-occlusive disease in children undergoing bone marrow transplantation.

Authors:  G Vassal; S Koscielny; D Challine; D Valteau-Couanet; I Boland; A Deroussent; J Lemerle; A Gouyette; O Hartmann
Journal:  Cancer Chemother Pharmacol       Date:  1996       Impact factor: 3.333

5.  Busulfan-melphalan in high-risk neuroblastoma: the 30-year experience of a single institution.

Authors:  S Proust-Houdemont; C Pasqualini; P Blanchard; C Dufour; E Benhamou; G Goma; M Semeraro; M-A Raquin; O Hartmann; D Valteau-Couanet
Journal:  Bone Marrow Transplant       Date:  2016-04-04       Impact factor: 5.483

6.  Correlation of tumour and treatment characteristics to dose received by cochlea in volumetric arc therapy.

Authors:  Nidhin Das; Sourabha Kumar Patro; Darwin Kaushal; Puneet Pareek; Abhinav Dixit; Sri Harsha Kombathula; Kapil Soni; Vidhu Sharma; Amit Goyal
Journal:  Eur Arch Otorhinolaryngol       Date:  2021-06-23       Impact factor: 2.503

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.